All Metrics
TECH Valuation Metrics
TECH Stock Price Metrics
TECH Dividend Metrics
TECH Growth Rate Metrics
TECH Discounted Cash Flow Metrics
| Fair Value Price | $22.75 |
| Margin of Safety | (67.95%) |
TECH Revenue Metrics
TECH PE Ratio Metrics
| PE Ratio | 102.90 |
| PE Ratio Avg TTM | 105.23 |
| PE Ratio Avg 3Y | 68.43 |
| Current VS TTM Avg | -2.21% |
| Current VS 3Y Avg | +50.37% |
| Current VS 5Y Avg | +38.39% |
TECH PS Ratio Metrics
| PS Ratio | 9.20 |
| PS Ratio Avg TTM | 7.32 |
| PS Ratio Avg 3Y | 8.92 |
| Current VS TTM Avg | +25.61% |
| Current VS 3Y Avg | +3.09% |
| Current VS 5Y Avg | -10.65% |
TECH PB Ratio Metrics
| PB Ratio | 5.34 |
| PB Ratio Avg TTM | 4.49 |
| PB Ratio Avg 3Y | 5.21 |
| Current VS TTM Avg | +19.01% |
| Current VS 3Y Avg | +2.48% |
| Current VS 5Y Avg | -15.11% |
TECH Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 41.33 |
| PFCF Ratio Avg TTM | 38.30 |
| PFCF Ratio Avg 3Y | 44.71 |
| Current VS TTM Avg | +7.91% |
| Current VS 3Y Avg | -7.56% |
| Current VS 5Y Avg | -13.83% |
TECH Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.14 |
| Debt/Equity Ratio Avg TTM | 0.19 |
| Debt/Equity Ratio Avg 3Y | 0.22 |
| Current VS TTM Avg | -27.16% |
| Current VS 3Y Avg | -35.84% |
| Current VS 5Y Avg | -34.34% |
TECH PEG Ratio Metrics
| PEG Ratio | - |
| PEG Ratio Avg TTM | 5.16 |
| PEG Ratio Avg 3Y | 3.55 |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | - |
| Current VS 5Y Avg | - |
TECH FCF Yield
| FCF Yield | 2.42% |
| FCF Yield Avg TTM | 2.61% |
| FCF Yield Avg 3Y | 2.30% |
| Current VS TTM Avg | -7.20% |
| Current VS 3Y Avg | +5.39% |
| Current VS 5Y Avg | +16.58% |
TECH Earnings Yield
| Earnings Yield | 0.97% |
| Earnings Yield Avg TTM | 1.02% |
| Earnings Yield Avg 3Y | 1.55% |
| Current VS TTM Avg | -5.03% |
| Current VS 3Y Avg | -37.42% |
| Current VS 5Y Avg | -37.54% |
TECH EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 73.00 |
| Ev/Ebit Ratio Avg TTM | 75.64 |
| Ev/Ebit Ratio Avg 3Y | 56.22 |
| Current VS TTM Avg | -3.49% |
| Current VS 3Y Avg | +29.85% |
| Current VS 5Y Avg | +24.32% |
TECH EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 44.17 |
| Ev/Ebitda Ratio Avg TTM | 39.94 |
| Ev/Ebitda Ratio Avg 3Y | 35.25 |
| Current VS TTM Avg | +10.60% |
| Current VS 3Y Avg | +25.32% |
| Current VS 5Y Avg | +20.97% |
TECH EV/Assets Ratio Metrics
| Ev/Assets Ratio | 4.40 |
| Ev/Assets Ratio Avg TTM | 3.58 |
| Ev/Assets Ratio Avg 3Y | 4.05 |
| Current VS TTM Avg | +22.79% |
| Current VS 3Y Avg | +8.68% |
| Current VS 5Y Avg | -9.77% |
TECH EV/Sales Ratio Metrics
| Ev/Sales Ratio | 9.27 |
| Ev/Sales Ratio Avg TTM | 7.52 |
| Ev/Sales Ratio Avg 3Y | 9.16 |
| Current VS TTM Avg | +23.28% |
| Current VS 3Y Avg | +1.15% |
| Current VS 5Y Avg | -11.73% |
TECH Current Ratio Metrics
| Current Ratio | 4.49 |
| Current Ratio Avg TTM | 4.08 |
| Current Ratio Avg 3Y | 4.21 |
| Current VS TTM Avg | +9.96% |
| Current VS 3Y Avg | +6.61% |
| Current VS 5Y Avg | +10.27% |
TECH Quick Ratio Metrics
| Quick Ratio | 3.18 |
| Quick Ratio Avg TTM | 2.80 |
| Quick Ratio Avg 3Y | 2.94 |
| Current VS TTM Avg | +13.26% |
| Current VS 3Y Avg | +8.03% |
| Current VS 5Y Avg | +7.87% |
TECH ROIC Metrics
| ROIC | 3.18% |
| ROIC Avg 3Y | 8.14% |
| ROIC Avg 5Y | 8.29% |
| Current VS 3Y Avg | -60.95% |
| Current VS 5Y Avg | -61.66% |
| Current VS 10Y Avg | -61.34% |
TECH Return on Assets Metrics
| ROA | 2.87% |
| ROA Avg TTM | 4.54% |
| ROA Avg 3Y | 7.94% |
| Current VS TTM Avg | -36.85% |
| Current VS 3Y Avg | -63.85% |
| Current VS 5Y Avg | -65.05% |
TECH Return on Equity Metrics
| ROE | 3.83% |
| ROE Avg TTM | 5.98% |
| ROE Avg 3Y | 10.62% |
| Current VS TTM Avg | -35.95% |
| Current VS 3Y Avg | -63.92% |
| Current VS 5Y Avg | -66.23% |
TECH Net Profit Margin Metrics
| Net Profit Margin | 16.40% |
| Net Profit Margin Avg TTM | 8.83% |
| Net Profit Margin Avg 3Y | 13.10% |
| Current VS TTM Avg | +85.74% |
| Current VS 3Y Avg | +25.17% |
| Current VS 5Y Avg | -7.67% |
Last Updated: Saturday, June 27, 2026
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman